This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reddy, J. A. Articles by Leamon, C. P. Search for Related Content PubMed PubMed Citation Articles by Reddy, J. A. Articles by Leamon, C. P.

Preclinical Evaluation of EC145, a Folate-Vinca Alkaloid Conjugate

Endocyte, Inc., West Lafayette, Indiana

Requests for reprints: Christopher P. Leamon, Endocyte Inc., 3000 Kent Avenue, Suite A1-100, West Lafayette, IN 47906. Phone: 765-463-7175; Fax: 765-463-9271; E-mail: Chrisleamon{at}endocyte.com.

We recently developed a new group of folate-conjugated Vinca alkaloids, one of which, EC145, emerged as a candidate for clinical development. Brief treatment of nude mice bearing 100 mm³ folate receptor-positive human xenografts led to complete response (CR) in 5/5 mice and cures (i.e., remission without a relapse for >90 days post-tumor implantation) in 4/5 mice. Multiple CRs and cures were also noted when EC145 was used to treat mice initially bearing tumors as large as 750 mm³. Likewise, complete cures (5/5) resulted following the treatment of an aggressive folate receptor–positive J6456 lymphoma model. The activity of EC145 was not accompanied by noticeable weight loss or major organ tissue degeneration. Furthermore, no significant antitumor activity (0/5 CR) was observed in EC145-treated animals that were co-dosed with an excess of a benign folate ligand, thus demonstrating the target-specific activity of EC145. The enhanced therapeutic index due to folate conjugation was also evidenced by the fact that the unconjugated drug (desacetylvinblastine monohydrazide) was found to be completely inactive when administered at nontoxic dose levels and only marginally active when given at highly toxic dose levels. Subsequent dose regimen studies confirmed that EC145 given on a more frequent, qdx5 schedule resulted in the most effective antitumor response as compared with an equivalent total dose given on thrice- or single-injection-per-week schedule. Taken together, these studies show that EC145 has significant antiproliferative activity and tolerability, thus lending support to an ongoing phase 1 trial for the treatment of advanced malignancies. [Cancer Res 2007;67(9):4434–42]

This article has been cited by other articles:

				R. E. Fisher, B. A. Siegel, S. L. Edell, N. M. Oyesiku, D. E. Morgenstern, R. A. Messmann, and R. J. Amato Exploratory Study of 99mTc-EC20 Imaging for Identifying Patients with Folate Receptor-Positive Solid Tumors J. Nucl. Med., June 1, 2008; 49(6): 899 - 906. [Abstract] [Full Text] [PDF]

				A. L Jackman Exploiting Folate Pathways and Transporters for the Management and Treatment of Cancer Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 101 - 108. [Abstract] [Full Text] [PDF]

				J. A. Reddy, E. Westrick, H. K.R. Santhapuram, S. J. Howard, M. L. Miller, M. Vetzel, I. Vlahov, R. V.J. Chari, V. S. Goldmacher, and C. P. Leamon Folate Receptor-Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate Cancer Res., July 1, 2007; 67(13): 6376 - 6382. [Abstract] [Full Text] [PDF]